Dr. Robert Maxson, M.D. Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 12255 S 80th Ave Ste 204, Palos Heights, IL 60463 Phone: 708-923-3388 Fax: 708-923-3380 |
Dr. Justin I Weiner, DO Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 12251 S 80th Ave Ste 1780, Palos Heights, IL 60463 Phone: 708-923-3420 Fax: 708-923-3399 |
Ayman O Alsharbini, DO Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 12251 S 80th Ave, Palos Heights, IL 60463 Phone: 708-923-3388 Fax: 708-923-5859 |
Thomas Quinn, M.D. Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 12255 S 80th Ave, Palos Heights, IL 60463 Phone: 708-923-3388 Fax: 708-923-3380 |
Nimit K Aggarwal, M.D. Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 12820 S Ridgeland Ave, Suite B, Palos Heights, IL 60463 Phone: 708-371-8006 Fax: 708-389-6630 |
News Archive
The neuropeptide αCGRP (α calcitonin gene-related peptide) works in two different ways. It leads to inflammation and dilates the blood vessels right at the release point of the nerve cells, for example in the meninges, which can trigger migraine attacks. However, it has a completely different effect on the heart, as has now been discovered by a team of researchers at the University of Zurich.
Researchers compared the responses against several SARS-CoV-2 VoCs in sera from individuals exposed to variant infection, vaccination, or both.
After the killing last year of George Floyd, a Black man, by a white Minneapolis police officer, Wisconsin Gov. Tony Evers declared racism a public health crisis. The governors of Michigan and Nevada quickly followed, as have legislative bodies in Minnesota, Virginia and Washington, D.C.
Researchers led by Carnegie Mellon University Professor of Biological Sciences Chien Ho have developed a new method for preparing mesenchymal stem cells (MSCs) that not only leads to the production of more native stem cells, but also labels them with a FDA approved iron-oxide nanoparticle (Ferumoxytol).
A multicenter team of investigators, led by researchers from the Cedars-Sinai Department of Neurosurgery, the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Dana-Farber Cancer Institute in Boston, have found in a Phase II clinical trial that an immune system-boosting therapy slowed the recurrence of glioblastoma multiforme, or GBM, the most common and deadly malignant brain tumor.
› Verified 2 days ago